



GOODWIN BIOTECHNOLOGY'S MANUFACTURED MELANIN-BINDING ANTIBODY USED IN SUCCESSFUL MELANOMA TRIAL

Plantation, FL, July 21, 2008 – **Goodwin Biotechnology Inc.** (GBI) today announced that the melanin-binding IgM antibody manufactured by the company was used in a successful Phase I clinical trial for the treatment of melanoma. The encouraging results, conducted by Pain Therapeutics, Inc. and its collaborators, were announced earlier this month. GBI was selected to develop the process and produce the preclinical and clinical material for this and future trials.

“We are pleased to have participated in this exciting project and look forward to continuing our work in the melanoma space,” said Stephanie Finnegan, chief executive officer of GBI.

Pain Therapeutics reported that top-line results of the Phase I trial indicate that the antibody binds to melanoma tumor sites, as evidenced by powerful imaging data obtained by planar scintigraphy and SPECT/CT (single photon emission computed tomography combined with computed tomography).

Pain Therapeutics plans to initiate a second trial in which patients will receive increasing amounts of radioactivity delivered by the radio-labeled antibody.

About Goodwin Biotechnology Inc.

GBI is one of the earliest contract manufacturing organizations (CMOs), established in 1992. GBI specializes in process development and cGMP compliant mammalian cell culture manufacturing of bio-therapeutics for pre-clinical studies through Phase III clinical trials. GBI's clients include small to mid-sized biotech companies throughout North America and Europe, universities, renowned cancer research institutes and various branches of the U.S. government. GBI offers its clients the experience of an established US Contract Manufacturing Organization, and provides services in a fully integrated offering, including process development, cell banking, GMP manufacture, conjugation, vialing, and distribution to the clinical trial sites. GBI is renowned for its niche expertise in serving clients from bench through clinic in monoclonal antibodies (including IgMs) and protein conjugation. www.goodwinbio.com

For more information, please contact:

Stephanie Finnegan, CEO
(954) 327-9606
sfinnegan@goodwinbio.com
1850 NW 69 Avenue
Plantation, Florida 33313